Get started
Author

A Garrison

Observed names: Adam M. Garrison, Andrew Garrison
OpenAlex ID: A5083074756
DOP38 Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy
2023 · J F Colombel, T Hisamatsu, et al. · Journal of Crohn s and Colitis · 5
PDF
OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics
2023 · L Peyrin-Biroulet, G Parkes, et al. · Journal of Crohn s and Colitis · 5
PDF
DOP18 Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial
2024 · L Peyrin-Biroulet, J F Colombel, et al. · Journal of Crohn s and Colitis · 3
PDF
DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib
2023 · M C Dubinsky, G D’Haens, et al. · Journal of Crohn s and Colitis · 2
PDF
P0561 Sustained Corticosteroid-Sparing Effects of Upadacitinib Maintenance Therapy in Patients With Moderate-to-Severe Crohn’s Disease: 2-Year Results From the U-ENDURE Long-Term Extension Study
2025 · V Jairath, M Dubinsky, et al. · Journal of Crohn s and Colitis · 1
P1008 Efficacy and safety of retreatment with upadacitinib after treatment interruption in ulcerative colitis: Data from the phase 3 open-label extension study U-ACTIVATE
2024 · R Panaccione, J F Colombel, et al. · Journal of Crohn s and Colitis · 1
PDF
DOP47 Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatment
2024 · R Panaccione, G Y Melmed, et al. · Journal of Crohn s and Colitis · 1
PDF
P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies
2023 · S Vermeire, S Danese, et al. · Journal of Crohn s and Colitis · 1
Durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s Disease: a post hoc analysis of part 2 of the SEQUENCE study
2026 · R Atreya, J O Lindsay, et al. · Zeitschrift für Gastroenterologie
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn’s disease: post hoc results from the phase 3b SEQUENCE trial
2026 · Tim Raine, Silvio Danese, et al. · Journal of Crohn s and Colitis
P185 Impact of concomitant 5-aminosalicyclic acid therapy on upadacitinib efficacy and safety in ulcerative colitis: phase 3 clinical trials post-hoc analyses
2026 · Charlotte Wong, James Crooks, et al. · E-Posters
P180 Durable efficacy of risankizumab through week 100 in patients with moderately to severely active crohn’s disease: SEQUENCE post hoc analysis
2026 · Raja Atreya, James O Lindsay, et al. · E-Posters
PDF
P1108 Upadacitinib improves histologic and endoscopic-histologic outcomes in the colon and ileum of patients with moderately to severely active Crohn’s disease
2026 · F Magro, V Jairath, et al. · Journal of Crohn s and Colitis
PDF
DOP004 Durable Efficacy of Risankizumab Through Week 148 in Patients With Moderate-to-Severe Crohn’s Disease: A Post Hoc Analysis of Part 2 of the SEQUENCE Study
2026 · R Atreya, J Lindsay, et al. · Journal of Crohn s and Colitis
P0895 Long-Term Efficacy of Upadacitinib in Patients With Moderate-to-Severe Crohn’s Disease and Prior Biologic Use
2026 · R Atreya, R Panaccione, et al. · Journal of Crohn s and Colitis
Sustained corticosteroid-sparing effects of upadacitinib maintenance therapy in patients with moderate-to-severe crohn’s disease: 2-year results from the U-ENDURE long-term extension study
2025 · I Blumenstein, V Jairath, et al. · Zeitschrift für Gastroenterologie
P0807 Impact of Risankizumab on Patient-reported Outcomes and Biomarkers Over Time: Post-Hoc Analysis of Phase 3 INSPIRE and COMMAND Studies
2025 · J Lindsay, M Ferrante, et al. · Journal of Crohn s and Colitis
P509 Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn’s disease
2024 · I Blumenstein, J Torres, et al. · Journal of Crohn s and Colitis
PDF
Association Between Sickle Cell Disease and Mortality and Hospitalizations Among In-Center Hemodialysis Patients
2023 · Derek M. Blankenship, Adam M. Garrison, et al. · Journal of the American Society of Nephrology
P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity
2023 · B Siegmund, K Patel, et al. · Journal of Crohn s and Colitis
PDF
Works count: 20
Citation count: 19
H-index: 3
I10-index:
Year
Topic
Type